Dr. Philippe Gabriel Steg

Ph. Gabriel Steg

Interventional cardiologist / Cardiologist
Hôpital Bichat - Paris, France

Declaration of interest

FunctionCompany
None

Latest contributions

Planned and ongoing clinical trials on adjunctive pharmacotherapy

18 May 2017 – From EuroPCR 2017

Hot line - Antithrombotic strategies

21 May 2015 – From EuroPCR 2015

Managing the patient with an acute coronary syndrome / coronary artery disease: optimising antiplatelet treatment and reducing future risk

18 May 2016 – From EuroPCR 2016

The year in intervention: essential publications from the EuroIntervention Journal and the European Heart Journal

18 May 2016 – From EuroPCR 2016

Prof. Patrick W. Serruys

Chairperson

Patrick W. Serruys

Antiplatelet pre-treatment: is earlier the better?

22 May 2015 – From EuroPCR 2015

Chairperson

Byung-Ryul Cho

Combined Factor Xa and platelet inhibition to prevent recurrent events after ACS: the story so far

21 May 2015 – From EuroPCR 2015

This video is offered by BAYER HEALTHCARE PHARMACEUTICALS

Innovation in cardiovascular pharmacology for the interventional cardiologist

21 May 2015 – From EuroPCR 2015

Prof. Ran Kornowski

Chairperson

Ran Kornowski

Mastering interventional pharmacotherapy for ACS

21 May 2014 – From EuroPCR 2014

Prof. Andreas Baumbach

Chairperson

Andreas Baumbach
Dr. Philippe Gabriel Steg

Chairperson

Ph. Gabriel Steg

New antiplatelet agents in ACS - Part I

21 May 2014 – From EuroPCR 2014

Chairperson

Luigi Di Serafino
Dr. Philippe Gabriel Steg

Chairperson

Ph. Gabriel Steg

The evolution of adjunctive antiplatelet therapy in non urgent PCI

21 May 2014 – From EuroPCR 2014

Chairperson

Hugo Katus
Prof. Patrick W. Serruys

Chairperson

Patrick W. Serruys

A new combination of Factor Xa inhibition and standard antiplatelet therapy to prevent more recurrent cardiovascular events after ACS

20 May 2014 – From EuroPCR 2014

Contemporary ACS antithrombotic therapy

23 May 2013 – From EuroPCR 2013

Click here to watch the VIDEO

Dr. Philippe Gabriel Steg

Chairperson

Ph. Gabriel Steg

Chairperson

C. Michael Gibson

A new combination of factor Xa inhibition and standard antiplatelet therapy to prevent more recurrent cardiovascular events in ACS

22 May 2013 – From EuroPCR 2013

Real-world considerations for selecting antiplatelet therapy in high-risk ACS patients: putting evidence into clinical practice

22 May 2013 – From EuroPCR 2013

Click here to watch the VIDEO